Look for:

Our offer for

VERTEX PHARMACEUTICAL


ISIN:
US92532F1003
WKN:
92532F100

2019/12/06 22:00:00
Price
223.25 USD
Difference 0.08% (0.18)

General attributes

ISINUS92532F1003
SymbolVRTX
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)51,515 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)219.05 USD (100)
Ask (Ask size)227.02 USD (100)
Open224.17 USD
High224.66 USD
Low220.36 USD
Close (prev. day)223.07 USD
VWAP222.618758 USD
Volume (pcs)1,021,307
Trading volume227,339,057.89
Number of trades15,560
Last size127,141

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: VERTEX PHARMACEUTICALPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2019/12/06 22:00:00
Price
223.25 USD
Difference 0.08% (0.18)

General attributes

ISINUS92532F1003
SymbolVRTX
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)51,515 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)219.05 USD (100)
Ask (Ask size)227.02 USD (100)
Open224.17 USD
High224.66 USD
Low220.36 USD
Close (prev. day)223.07 USD
VWAP222.618758 USD
Volume (pcs)1,021,307
Trading volume227,339,057.89
Number of trades15,560
Last size127,141

Performance and Risk

6m1Y3Y
Perf (%)+33.03%+24.30%+185.78%
Perf (abs.)+55.43+43.64+145.13
Beta0.871.091.23
Volatility26.0628.8933.15
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)222.43 USD (955,197)
Ø price 30 days | Ø volume 30 days (pcs.)208.98 USD (1,331,175)
Ø price 100 days | Ø volume 100 days (pcs.)186.22 USD (1,265,887)
Ø price 250 days | Ø volume 250 days (pcs.)181.37 USD (1,297,865)
YTD High | date224.66 USD (2019/12/06)
YTD Low | date160.95 USD (2019/01/02)
52 Weeks High | date224.66 USD (2019/12/06)
52 Weeks Low | date151.80 USD (2018/12/24)

All listings for VERTEX PHARMACEUTICAL

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Xetra2019/12/0910:43205.00 EUR0.001
Vienna Stock Exchange2019/12/0909:05201.80 EUR0.001
Tradegate2019/12/0911:01201.10 EUR0.013
Stuttgart2019/12/0909:13201.15 EUR0.002
Nasdaq2019/12/0622:00223.25 USD227.3415,560
Munich2019/12/0908:00201.05 EUR0.001
London Stock Exchange2019/09/2718:34167.6700 USD0.001
Hanover2019/12/0908:05201.05 EUR0.001
Hamburg2019/12/0908:05201.05 EUR0.001
Frankfurt2019/12/0908:10201.05 EUR0.001
Duesseldorf2019/12/0911:07201.00 EUR0.003
Berlin2019/12/0908:08201.20 EUR0.001

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=15368&ID_TYPE_IMAGE_LOGO=2

Contact Details

VERTEX PHARMACEUTICALS INC.
Michael Partridge
Northern Avenue 50 02210 Boston, Massachusetts
Telefon: +1-617-341-6100
Fax: -
E-mail: investorinfo@vrtx.com

PDF Downloads

Company report: VERTEX PHARMACEUTICALPDF Download

Company Profile

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.

Members of Management Board

Jeffrey LeidenChairman of Board of Directors
Yuchun LeeMember of Board of Directors
Terrence C. KearneyMember of Board of Directors
Margaret McGlynnMember of Board of Directors
Lloyd CarneyMember of Board of Directors
Bruce I. SachsMember of Board of Directors
William YoungMember of Board of Directors
Sangeeta N. BhatiaMember of Board of Directors
Alan GarberMember of Board of Directors
Jeffrey LeidenChairman of Managing Board
Stuart A. ArbuckleMember of Executive Committee
Stephanie FranklinMember of Executive Committee
Paul NegulescuMember of Executive Committee
Nina DevlinMember of Executive Committee
Nia Tatsis, Ph.D.Member of Executive Committee
Michael J. PariniMember of Executive Committee
Michael PartridgeMember of Executive Committee
Mark BunnageMember of Executive Committee
Ludovic FenauxMember of Executive Committee
Damian WimotMember of Executive Committee
Charles F. Wagner, Jr.Member of Executive Committee
Carmen Bozic, M.D.Member of Executive Committee
Amit K. SachdevMember of Executive Committee
Reshma KewalramaniMember of Executive Committee
David AltshulerMember of Executive Committee






Accept

We use cookies and web analysis software to give you the best possible experience on our website. By continuing to browse this website, you consent for these tools to be used. For more details and how to opt out of these, please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer